Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.1467 | 1 | 1 |
Brugia malayi | metabotropic glutamate receptor subtype 5a (mGluR5a), putative | 0.108 | 0.6119 | 0.8166 |
Plasmodium falciparum | beta-ketoacyl-ACP synthase III | 0.1027 | 0.5586 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | 3-oxoacyl-ACP synthase | 0.1027 | 0.5586 | 0.5 |
Echinococcus multilocularis | metabotropic glutamate receptor 5 | 0.1467 | 1 | 1 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.1027 | 0.5586 | 0.5 |
Schistosoma mansoni | metabotropic glutamate receptor | 0.0999 | 0.5304 | 0.5392 |
Loa Loa (eye worm) | glutamate receptor | 0.1192 | 0.7241 | 0.7241 |
Chlamydia trachomatis | oxoacyl-ACP synthase III | 0.1027 | 0.5586 | 0.5 |
Mycobacterium ulcerans | beta-ketoacyl synthase-like protein | 0.1027 | 0.5586 | 0.5 |
Mycobacterium tuberculosis | 3-oxoacyl-[acyl-carrier-protein] synthase III FabH (beta-ketoacyl-ACP synthase III) (KAS III) | 0.1027 | 0.5586 | 0.5 |
Brugia malayi | Metabotropic glutamate receptor precursor. | 0.1192 | 0.7241 | 1 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.1027 | 0.5586 | 0.5 |
Plasmodium vivax | beta-ketoacyl-acyl carrier protein synthase III precursor, putative | 0.1027 | 0.5586 | 0.5 |
Schistosoma mansoni | metabotropic glutamate receptor 2 3 (mglur group 2) | 0.1355 | 0.8878 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
MED (functional) | = 100 mg kg-1 | Anticonvulsant activity in ip dosed CF1 albino mouse assessed as protection against maximal electroshock after 0.5 hrs | ChEMBL. | 21840629 |
MED (functional) | = 100 mg kg-1 | Anticonvulsant activity in ip dosed CF1 albino mouse assessed as protection against maximal electroshock after 4 hrs | ChEMBL. | 21840629 |
MTC (ADMET) | = 300 mg kg-1 | Neurotoxicity in ip dosed CF1 albino mouse assessed as minimum dose required to cause motor impairment after 0.5 hrs by rotarod test | ChEMBL. | 21840629 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.